Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M, Hamada C, Tanaka M, Akimoto M, Nakamura K, et al.; Writing Group Edaravone (MCI-186) ALS 19 Study Group (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16:505–512.
Aguirre-Plans J, Piñero J, Menche J, Sanz F, Furlong LI, Schmidt HHHW, Oliva B, and Guney E (2018) Proximal pathway enrichment analysis for targeting comorbid diseases via network endopharmacology. Pharmaceuticals (Basel) 11:61.
Ahmadinejad F, Geir Møller S, Hashemzadeh-Chaleshtori M, Bidkhori G, and Jami M-S (2017) Molecular mechanisms behind free radical scavengers function against oxidative stress. Antioxidants 6:51.
Akaike T, Ando M, Oda T, Doi T, Ijiri S, Araki S, and Maeda H (1990) Dependence on O2-generation by xanthine oxidase of pathogenesis of influenza virus infection in mice. J Clin Invest 85:739–745.
Alem MMA, Alshehri AMA, Cahusac PM, and Walters MR (2018) Effect of xanthine oxidase inhibition on arterial stiffness in patients with chronic heart failure. Clin Med Insights Cardiol 12:1179546818779584.
Alexander, JH, Reynolds, HR, Stebbins, AL, Dzavik, V, Harrington, RA, et al.; TRIUMPH Investigators (2007) Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 297:1657–1666.
Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029–1035.
Altenhöfer S, Radermacher KA, Kleikers PWM, Wingler K, and Schmidt HHHW (2015) Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement. Antioxid Redox Signal 23:406–427.
Ames BN (1989) Endogenous DNA damage as related to cancer and aging. Mutat Res 214:41–46.
Ameziane-El-Hassani R, Schlumberger M, and Dupuy C (2016) NADPH oxidases: new actors in thyroid cancer? Nat Rev Endocrinol 12:485–494.
Anderson EJ, Efird JT, Davies SW, O’Neal WT, Darden TM, Thayne KA, Katunga LA, Kindell LC, Ferguson TB, Anderson CA, et al. (2014) Monoamine oxidase is a major determinant of redox balance in human atrial myocardium and is associated with postoperative atrial fibrillation. J Am Heart Assoc 3:e000713.
Antoniades C, Shirodaria C, Leeson P, Antonopoulos A, Warrick N, Van-Assche T, Cunnington C, Tousoulis D, Pillai R, Ratnatunga C, et al. (2009) Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J 30:1142–1150.
Anvari E, Wikström P, Walum E, and Welsh N (2015) The novel NADPH oxidase 4 inhibitor GLX351322 counteracts glucose intolerance in high-fat diet-treated C57BL/6 mice. Free Radic Res 49:1308–1318.
Arsenijevic D, Onuma H, Pecqueur C, Raimbault S, Manning BS, Miroux B, Couplan E, Alves-Guerra M-C, Goubern M, Surwit R, et al. (2000) Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production. Nat Genet 26:435–439.
Ashor AW, Lara J, Mathers JC, and Siervo M (2014) Effect of vitamin C on endothelial function in health and disease: a systematic review and meta-analysis of randomised controlled trials. Atherosclerosis 235:9–20.
Augsburger F, Filippova A, Rasti D, Seredenina T, Lam M, Maghzal G, Mahiout Z, Jansen-Dürr P, Knaus UG, Doroshow J, et al. (2019) Pharmacological characterization of the seven human NOX isoforms and their inhibitors. Redox Biol 26:101272.
Bainton DF, Ullyot JL, and Farquhar MG (1971) The development of neutrophilic polymorphonuclear leukocytes in human bone marrow. J Exp Med 134:907–934.
Bartoli F, Trotta G, Crocamo C, Malerba MR, Clerici M, and Carrà G (2018) Anti-oxidant uric acid in treated and untreated subjects with major depressive disorder: a meta-analysis and meta-regression. Eur Arch Psychiatry Clin Neurosci 268: 119–127.
Bas DF, Topcuoglu MA, Gursoy-Ozdemir Y, Saatci I, Bodur E, and Dalkara T (2012) Plasma 3-nitrotyrosine estimates the reperfusion-induced cerebrovascular stress, whereas matrix metalloproteinases mainly reflect plasma activity: a study in patients treated with thrombolysis or endovascular recanalization. J Neurochem 123 (Suppl 2):138–147.
Battelli MG, Lorenzoni E, and Stripe F (1973) Milk xanthine oxidase type D (de-hydrogenase) and type O (oxidase). Purification, interconversion and some prop-erties. Biochem J 131:191–198.
Békési G, Heinle H, Kakucs R, Pázmány T, Szombath D, Dinya M, Tulassay Z, Fehér J, Rácz K, Székács B, et al. (2005) Effect of inhibitors of myeloperoxidase on the development of aortic atherosclerosis in an animal model. Exp Gerontol 40: 199–208.
Bellezza I, Giambanco I, Minelli A, and Donato R (2018) Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim Biophys Acta Mol Cell Res 1865:721–733.
Bensalem S, Soubhye J, Aldib I, Bournine L, Nguyen AT, Vanhaeverbeek M, Rous-seau A, Boudjeltia KZ, Sarakbi A, Kauffmann JM, et al. (2014) Inhibition of myeloperoxidase activity by the alkaloids of Peganum harmala L. (Zygophylla-ceae). J Ethnopharmacol 154:361–369.
Berry CE and Hare JM (2004) Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555: 589–606.
Bianchi P, Kunduzova O, Masini E, Cambon C, Bani D, Raimondi L, Seguelas M-H, Nistri S, Colucci W, Leducq N, et al. (2005) Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and post-ischemic myocardial injury. Circulation 112:3297–3305.
Binda C, Newton-Vinson P, Hubálek F, Edmondson DE, and Mattevi A (2002) Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol 9:22–26.
Bjelakovic G and Gluud C (2007) Surviving antioxidant supplements. J Natl Cancer Inst 99:742–743.
Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, and Gluud C (2007) Mortality in randomized trials of antioxidant supplements for primary and secondary pre-vention: systematic review and meta-analysis. JAMA 297:842–857.
Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, and Gluud C (2012) Anti-oxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev:CD007176 DOI: 10.1002/14651858.CD007176.pub2.
Bjelakovic G, Nikolova D, Simonetti RG, and Gluud C (2004) Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 364:1219–1228.
Bkaily G, Najibeddine W, and Jacques D (2019) Increase of NADPH oxidase 3 in heart failure of hereditary cardiomyopathy1. Can J Physiol Pharmacol 97: 902–908.
Bömmel HM, Reif A, Fröhlich LG, Frey A, Hofmann H, Marecak DM, Groehn V, Kotsonis P, La M, Köster S, et al. (1998) Anti-pterins as tools to characterize the function of tetrahydrobiopterin in NO synthase. J Biol Chem 273:33142–33149.
Bomprezzi R (2015) Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview. Ther Adv Neurol Disord 8:20–30.
Bortolato M, Chen K, and Shih JC (2008) Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev 60:1527–1533.
Bortolato M and Shih JC (2011) Behavioral outcomes of monoamine oxidase de-ficiency: preclinical and clinical evidence. Int Rev Neurobiol 100:13–42.
Boustany-Kari CM, Harrison PC, Chen H, Lincoln KA, Qian HS, Clifford H, Wang H, Zhang X, Gueneva-Boucheva K, Bosanac T, et al. (2016) A soluble guanylate cy-clase activator inhibits the progression of diabetic nephropathy in the ZSF1 rat. J Pharmacol Exp Ther 356:712–719.
Braga TT, Forni MF, Correa-Costa M, Ramos RN, Barbuto JA, Branco P, Castoldi A, Hiyane MI, Davanso MR, Latz E, et al. (2017) Soluble uric acid activates the NLRP3 inflammasome. Sci Rep 7:39884.
Breitenstein S, Roessig L, Sandner P, and Lewis KS (2017) Novel sGC stimulators and sGC activators for the treatment of heart failure. Handb Exp Pharmacol 243: 225–247.
Brennan M, Gaur A, Pahuja A, Lusis AJ, and Reynolds WF (2001) Mice lacking myeloperoxidase are more susceptible to experimental autoimmune encephalo-myelitis. J Neuroimmunol 112:97–105.
Burgoyne JR, Madhani M, Cuello F, Charles RL, Brennan JP, Schroder E, Browning DD, and Eaton P (2007) Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science 317:1393–1397.
Burgoyne JR, Rudyk O, Cho HJ, Prysyazhna O, Hathaway N, Weeks A, Evans R, Ng T, Schröder K, Brandes RP, et al. (2015) Deficient angiogenesis in redox-dead Cys17Ser PKARIα knock-in mice. Nat Commun 6:7920.
Butts B, Calhoun DA, Denney TS Jr., Lloyd SG, Gupta H, Gaddam KK, Aban I, Oparil S, Sanders PW, Patel R, et al. (2019) Plasma xanthine oxidase activity is related to increased sodium and left ventricular hypertrophy in resistant hyper-tension. Free Radic Biol Med 134:343–349.
Caldera M, Müller F, Kaltenbrunner I, Licciardello MP, Lardeau C-H, Kubicek S, and Menche J (2019) Mapping the perturbome network of cellular perturbations. Nat Commun 10:5140.
Carnesecchi S, Deffert C, Donati Y, Basset O, Hinz B, Preynat-Seauve O, Guichard C, Arbiser JL, Banfi B, Pache J-C, et al. (2011) A key role for NOX4 in epithelial cell death during development of lung fibrosis. Antioxid Redox Signal 15: 607–619.
Carpi A, Menabò R, Kaludercic N, Pelicci P, Di Lisa F, and Giorgio M (2009) The cardioprotective effects elicited by p66(Shc) ablation demonstrate the crucial role of mitochondrial ROS formation in ischemia/reperfusion injury. Biochim Biophys Acta 1787:774–780.
Carr AC, Vissers MCM, and Cook JS (2014) The effect of intravenous vitamin C on cancer-and chemotherapy-related fatigue and quality of life. Front Oncol 4:283.
Casas AI, Dao VT-V, Daiber A, Maghzal GJ, Di Lisa F, Kaludercic N, Leach S, Cuadrado A, Jaquet V, Seredenina T, et al. (2015) Reactive oxygen-related dis-eases: therapeutic targets and emerging clinical indications. Antioxid Redox Signal 23:1171–1185.
Casas AI, Geuss E, Kleikers PWM, Mencl S, Herrmann AM, Buendia I, Egea J, Meuth SG, Lopez MG, Kleinschnitz C, et al. (2017) NOX4-dependent neuronal autotoxicity and BBB breakdown explain the superior sensitivity of the brain to ischemic damage. Proc Natl Acad Sci USA 114:12315–12320.
Casas AI, Hassan AA, Larsen SJ, Gomez-Rangel V, Elbatreek M, Kleikers PWM, Guney E, Egea J, López MG, Baumbach J, et al. (2019a) From single drug targets to synergistic network pharmacology in ischemic stroke. Proc Natl Acad Sci USA 116:7129–7136.
Casas AI, Kleikers PWM, Geuss E, Langhauser F, Adler T, Busch DH, Gailus-Durner V, de Angelis MH, Egea J, Lopez MG, et al. (2019b) Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke. J Clin Invest 130:1772–1778.
Cascorbi I, Henning S, Brockmöller J, Gephart J, Meisel C, Müller JM, Lod-denkemper R, and Roots I (2000) Substantially reduced risk of cancer of the aer-odigestive tract in subjects with variant--463A of the myeloperoxidase gene. Cancer Res 60:644–649.
Caviedes A, Varas-Godoy M, Lafourcade C, Sandoval S, Bravo-Alegria J, Kaehne T, Massmann A, Figueroa JP, Nualart F, and Wyneken U (2017) Endothelial nitric oxide synthase is present in dendritic spines of neurons in primary cultures. Front Cell Neurosci 11:180.
Cavusoglu E, Ruwende C, Eng C, Chopra V, Yanamadala S, Clark LT, Pinsky DJ, and Marmur JD (2007) Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol 99:1364–1368.
Cha JJ, Min HS, Kim KT, Kim JE, Ghee JY, Kim HW, Lee JE, Han JY, Lee G, Ha HJ, et al. (2017) APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury. Lab Invest 97:419–431.
Chakrabarti S, Chan CK, Jiang Y, and Davidge ST (2012) Neuronal nitric oxide synthase regulates endothelial inflammation. J Leukoc Biol 91:947–956.
Chen D, Liu X, Yang Y, Yang H, and Lu P (2015) Systematic synergy modeling: understanding drug synergy from a systems biology perspective. BMC Syst Biol 9:56.
Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, and Levine M (2008) Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 105:11105–11109.
Cheng M-L, Chen C-M, Gu P-W, Ho H-Y, and Chiu DT-Y (2008) Elevated levels of myeloperoxidase, white blood cell count and 3-chlorotyrosine in Taiwanese patients with acute myocardial infarction. Clin Biochem 41:554–560.
Choi D-K, Pennathur S, Perier C, Tieu K, Teismann P, Wu DC, Jackson-Lewis V, Vila M, Vonsattel JP, Heinecke JW, et al. (2005) Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson’s disease in mice. J Neurosci 25: 6594–6600.
Choi SA, Kim YH, Park YH, Yang HJ, Jeong PS, Cha JJ, Yoon SB, Kim JS, Song BS, Lee JH, et al. (2019) Novel crosstalk between Vps26a and Nox4 signaling during neurogenesis. Cell Death Differ 26:1582–1599 DOI: 10.1038/s41418-018-0226-0.
Choobdar S, Ahsen ME, Crawford J, Tomasoni M, Fang T, Lamparter D, Lin J, Hescott B, Hu X, Mercer J, et al.; DREAM Module Identification Challenge Consortium (2019) Assessment of network module identification across complex dis-eases. Nat Methods 16:843–852.
Cochemé HM and Murphy MP (2010) Can antioxidants be effective therapeutics? Curr Opin Investig Drugs 11:426–431.
Collins R, Armitage J, Parish S, Sleight P, and Peto R; Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:23–33.
Costell MH, Ancellin N, Bernard RE, Zhao S, Upson JJ, Morgan LA, Maniscalco K, Olzinski AR, Ballard VLT, Herry K, et al. (2012) Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress. Front Pharmacol 3:128.
Crabtree MJ and Channon KM (2011) Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease. Nitric Oxide 25:81–88.
Crabtree MJ, Tatham AL, Hale AB, Alp NJ, and Channon KM (2009) Critical role for tetrahydrobiopterin recycling by dihydrofolate reductase in regulation of endothelial nitric-oxide synthase coupling: relative importance of the de novo biopterin synthesis versus salvage pathways. J Biol Chem 284:28128–28136.
Crosas-Molist E, Bertran E, Rodriguez-Hernandez I, Herraiz C, Cantelli G, Fabra À, Sanz-Moreno V, and Fabregat I (2017) The NADPH oxidase NOX4 represses epithelial to amoeboid transition and efficient tumour dissemination. Oncogene 36: 3002–3014.
Cuadrado A, Manda G, Hassan A, Alcaraz MJ, Barbas C, Daiber A, Ghezzi P, León R, López MG, Oliva B, et al. (2018) Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach. Pharmacol Rev 70:348–383.
Cuadrado A, Rojo AI, Wells G, Hayes JD, Cousin SP, Rumsey WL, Attucks OC, Franklin S, Levonen A-L, Kensler TW, et al. (2019) Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov 18: 295–317.
Dao VT-V, Casas AI, Maghzal GJ, Seredenina T, Kaludercic N, Robledinos-Anton N, Di Lisa F, Stocker R, Ghezzi P, Jaquet V, et al. (2015) Pharmacology and clinical drug candidates in redox medicine. Antioxid Redox Signal 23:1113–1129.
Dao VT-V, Elbatreek MH, Altenhöfer S, Casas AI, Pachado MP, Neullens CT, Knaus UG, and Schmidt HHHW (2020) Isoform-selective NADPH oxidase inhibitor panel for pharmacological target validation. Free Radic Biol Med 148:60–69.
Dasgupta A, Bowman L, D’Arsigny CL, and Archer SL (2015) Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Clin Pharmacol Ther 97:88–102.
Dawson J, Broomfield N, Dani K, Dickie DA, Doney A, Forbes K, Houston G, Kean S, Lees K, McConnachie A, et al. (2018) Xanthine oxidase inhibition for the im-provement of long-term outcomes following ischaemic stroke and transient ischaemic attack (XILO-FIST)-protocol for a randomised double blind placebo-controlled clinical trial. Eur Stroke J 3:281–290.
De Colibus L, Li M, Binda C, Lustig A, Edmondson DE, and Mattevi A (2005) Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc Natl Acad Sci USA 102: 12684–12689.
de Gaetano G; Collaborative Group of the Primary Prevention Project (2001) Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 357:89–95.
Deliyanti D and Wilkinson-Berka JL (2015) Inhibition of NOX1/4 with GKT137831: a potential novel treatment to attenuate neuroglial cell inflammation in the retina. J Neuroinflammation 12:136.
Delporte C, Boudjeltia KZ, Noyon C, Furtmüller PG, Nuyens V, Slomianny M-C, Madhoun P, Desmet J-M, Raynal P, Dufour D, et al. (2014) Impact of myeloperoxidase-LDL interactions on enzyme activity and subsequent post-translational oxidative modifications of apoB-100. J Lipid Res 55:747–757.
Deshwal S, Forkink M, Hu C-H, Buonincontri G, Antonucci S, Di Sante M, Murphy MP, Paolocci N, Mochly-Rosen D, Krieg T, et al. (2018) Monoamine oxidase-dependent endoplasmic reticulum-mitochondria dysfunction and mast cell de-granulation lead to adverse cardiac remodeling in diabetes. Cell Death Differ 25: 1671–1685.
Di Marco E, Gray SP, Chew P, Kennedy K, Cooper ME, Schmidt HHHW, and Jandeleit-Dahm KAM (2016) Differential effects of NOX4 and NOX1 on immune cell-mediated inflammation in the aortic sinus of diabetic ApoE-/-mice. Clin Sci (Lond) 130:1363–1374.
Di Meo S, Reed TT, Venditti P, and Victor VM (2016) Role of ROS and RNS sources in physiological and pathological conditions. Oxid Med Cell Longev 2016:1245049.
Di Minno A, Turnu L, Porro B, Squellerio I, Cavalca V, Tremoli E, and Di Minno MN (2016) 8-Hydroxy-2-Deoxyguanosine levels and cardiovascular disease: a systematic review and meta-analysis of the literature. Antioxid Redox Signal 24:548–555 DOI: 10.1089/ars.2015.6508.
Diebold BA, Smith SME, Li Y, and Lambeth JD (2015) NOX2 as a target for drug development: indications, possible complications, and progress. Antioxid Redox Signal 23:375–405.
Dikalov SI and Harrison DG (2014) Methods for detection of mitochondrial and cellular reactive oxygen species. Antioxid Redox Signal 20:372–382.
Ding J-D, Burette A, Nedvetsky PI, Schmidt HHHW, and Weinberg RJ (2004) Dis-tribution of soluble guanylyl cyclase in the rat brain. J Comp Neurol 472:437–448.
Dinkova-Kostova AT, Talalay P, Sharkey J, Zhang Y, Holtzclaw WD, Wang XJ, David E, Schiavoni KH, Finlayson S, Mierke DF, et al. (2010) An exceptionally potent inducer of cytoprotective enzymes: elucidation of the structural features that de-termine inducer potency and reactivity with Keap1. J Biol Chem 285:33747–33755.
Dröge W (2002) Free radicals in the physiological control of cell function. Physiol Rev 82:47–95.
Duclos F, Abell LM, Harden DG, Pike K, Nowak K, Locke GA, Duke GJ, Liu X, Fernando G, Shaw SA, et al. (2017) Triazolopyrimidines identified as reversible myeloperoxidase inhibitors. MedChemComm 8:2093–2099.
Ebrahim S (2001) The use of numbers needed to treat derived from systematic reviews and meta-analysis. Caveats and pitfalls. Eval Health Prof 24:152–164.
Eidelman RS, Hollar D, Hebert PR, Lamas GA, and Hennekens CH (2004) Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch Intern Med 164:1552–1556.
Eigeldinger-Berthou S, Meier C, Zulliger R, Lecaudé S, Enzmann V, and Sarra G-M (2012) Rasagiline interferes with neurodegeneration in the Prph2/rds mouse. Retina 32:617–628.
Eiserich JP, Baldus S, Brennan M-L, Ma W, Zhang C, Tousson A, Castro L, Lusis AJ, Nauseef WM, Roger White C, et al. (2002) Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 296:2391–2394.
Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HHHW, and Stasch J-P (2006) NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5:755–768.
Fabbri M, Rosa MM, Abreu D, and Ferreira JJ (2015) Clinical pharmacology review of safinamide for the treatment of Parkinson’s disease. Neurodegener Dis Manag 5: 481–496.
Fantacuzzi M, Maccallini C, Di Matteo M, Ammazzalorso A, Bruno I, De Filippis B, Giampietro L, Mollica A, and Amoroso R (2016) Screening of NOS activity and selectivity of newly synthesized acetamidines using RP-HPLC. J Pharm Biomed Anal 120:419–424.
Farinacci M, Krahn T, Dinh W, Volk H-D, Düngen H-D, Wagner J, Konen T, and von Ahsen O (2018) Circulating endothelial cells as biomarker for cardiovascular dis-eases. Res Pract Thromb Haemost 3:49–58.
Feig DI, Mazzali M, Kang D-H, Nakagawa T, Price K, Kannelis J, and Johnson RJ (2006) Serum uric acid: a risk factor and a target for treatment? J Am Soc Nephrol 17 (4 Suppl 2):S69–S73.
Feng S, Yang Q, Liu M, Li W, Yuan W, Zhang S, Wu B, and Li J (2011) Edaravone for acute ischaemic stroke. Cochrane Database Syst Rev:CD007230 DOI: 10.1002/14651858.CD007230.pub2.
Fiedler TJ, Davey CA, and Fenna RE (2000) X-ray crystal structure and characterization of halide-binding sites of human myeloperoxidase at 1.8 A resolution. J Biol Chem 275:11964–11971.
Finberg JPM (2014) Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther 143:133–152.
Finkel T (2012) From sulfenylation to sulfhydration: what a thiolate needs to toler-ate. Sci Signal 5:pe10.
Fisar Z (2016) Drugs related to monoamine oxidase activity. Prog Neuro-psychopharmacol Biol Psychiatry 69:112–124.
Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, Fey P, Griebenow N, Kroh W, Becker-Pelster E-M, et al. (2017) Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure. J Med Chem 60:5146–5161.
Forghani R, Wojtkiewicz GR, Zhang Y, Seeburg D, Bautz BRM, Pulli B, Milewski AR, Atkinson WL, Iwamoto Y, Zhang ER, et al. (2012) Demyelinating diseases: myelo-peroxidase as an imaging biomarker and therapeutic target. Radiology 263:451–460.
Förstermann U, Schmidt HHHW, Kohlhaas KL, and Murad F (1992) Induced RAW 264.7 macrophages express soluble and particulate nitric oxide synthase: inhibition by transforming growth factor-β. Eur J Pharmacol 225:161–165.
Fowler JS, Volkow ND, Wang G-J, Logan J, Pappas N, Shea C, and MacGregor R (1997) Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging 18:431–435.
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, et al.; CONFIRM Study Investigators (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367:1087–1097.
Francis SH, Busch JL, Corbin JD, and Sibley D (2010) cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 62:525–563.
Fröhlich LG, Kotsonis P, Traub H, Taghavi-Moghadam S, Al-Masoudi N, Hofmann H, Strobel H, Matter H, Pfleiderer W, and Schmidt HHHW (1999) Inhibition of neuronal nitric oxide synthase by 4-amino pteridine derivatives: structure-activity relationship of antagonists of (6R)-5,6,7,8-tetrahydrobiopterin cofactor. J Med Chem 42:4108–4121.
Gellhaar S, Sunnemark D, Eriksson H, Olson L, and Galter D (2017) Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson’s and Alzheimer’s disease. Cell Tissue Res 369:445–454.
Ghezzi P, Bianchi M, Mantovani A, Spreafico F, and Salmona M (1984) Enhanced xanthine oxidase activity in mice treated with interferon and interferon inducers. Biochem Biophys Res Commun 119:144–149.
Ghezzi P, Jaquet V, Marcucci F, and Schmidt HHHW (2017) The oxidative stress theory of disease: levels of evidence and epistemological aspects. Br J Pharmacol 174:1784–1796.
Ghiassian SD, Menche J, Chasman DI, Giulianini F, Wang R, Ricchiuto P, Aikawa M, Iwata H, Müller C, Zeller T, et al. (2016) Endophenotype network models: common core of complex diseases. Sci Rep 6:27414.
Golubinskaya V, Brandt-Eliasson U, Gan L-M, Kjerrulf M, and Nilsson H (2014) Endothelial function in a mouse model of myeloperoxidase deficiency. BioMed Res Int 2014:128046.
Granger DN, Rutili G, and McCord JM (1981) Superoxide radicals in feline intestinal ischemia. Gastroenterology 81:22–29.
Gray SP, Di Marco E, Kennedy K, Chew P, Okabe J, El-Osta A, Calkin AC, Biessen EAL, Touyz RM, Cooper ME, et al. (2016) Reactive oxygen species can provide atheroprotection via NOX4-dependent inhibition of inflammation and vascular remodeling. Arterioscler Thromb Vasc Biol 36:295–307.
Green PS, Mendez AJ, Jacob JS, Crowley JR, Growdon W, Hyman BT, and Heinecke JW (2004) Neuronal expression of myeloperoxidase is increased in Alzheimer’s disease. J Neurochem 90:724–733.
Gulyás B, Pavlova E, Kása P, Gulya K, Bakota L, Várszegi S, Keller E, Horváth MC, Nag S, Hermecz I, et al. (2011) Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiog-raphy. Neurochem Int 58:60–68.
Hardiman O and van den Berg LH (2017) Edaravone: a new treatment for ALS on the horizon? Lancet Neurol 16:490–491.
Harman D (1956) Aging: a theory based on free radical and radiation chemistry. J Gerontol 11:298–300.
Harman D (1972) The biologic clock: the mitochondria? J Am Geriatr Soc 20:145–147.
Harris HR, Orsini N, and Wolk A (2014) Vitamin C and survival among women with breast cancer: a meta-analysis. Eur J Cancer 50:1223–1231.
Hayes P, Dhillon S, O’Neill K, Thoeni C, Hui KY, Elkadri A, Guo CH, Kovacic L, Aviello G, Alvarez LA, et al. (2015) Defects in NADPH oxidase genes NOX1 and DUOX2 in very early onset inflammatory bowel disease. Cell Mol Gastroenterol Hepatol 1:489–502.
Hazen SL and Heinecke JW (1997) 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipo-protein isolated from human atherosclerotic intima. J Clin Invest 99:2075–2081.
Heffron SP, Parastatidis I, Cuchel M, Wolfe ML, Tadesse MG, Mohler ER III, Ischiropoulos H, Rader DJ, and Reilly MP (2009) Inflammation induces fibrinogen nitration in experimental human endotoxemia. Free Radic Biol Med 47:1140–1146.
Hegele RA (2000) Angiotensin-converting enzyme (ACE) inhibition in the secondary prevention of vascular disease: The Heart Outcomes Prevention Evaluation (HOPE) trial and its substudies. Curr Atheroscler Rep 2:361–362.
Henrickson SE, Jongco AM, Thomsen KF, Garabedian EK, and Thomsen IP (2018) Noninfectious manifestations and complications of chronic granulomatous disease. J Pediatric Infect Dis Soc 7 (Suppl 1):S18–S24.
Herce-Pagliai C, Kotecha S, and Shuker DEG (1998) Analytical methods for 3-nitrotyrosine as a marker of exposure to reactive nitrogen species: a review. Nitric Oxide 2:324–336.
Heringa SM, van den Berg E, Reijmer YD, Nijpels G, Stehouwer CDA, Schalkwijk CG, Teerlink T, Scheffer PG, van den Hurk K, Kappelle LJ, et al. (2014) Markers of low-grade inflammation and endothelial dysfunction are related to reduced in-formation processing speed and executive functioning in an older population-the Hoorn Study. Psychoneuroendocrinology 40:108–118.
Higgins P, Dawson J, Lees KR, McArthur K, Quinn TJ, and Walters MR (2012) Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther 30:217–226.
Hirano K, Chen WS, Chueng ALW, Dunne AA, Seredenina T, Filippova A, Ramachandran S, Bridges A, Chaudry L, Pettman G, et al. (2015) Discovery of GSK2795039, a novel small molecule NADPH oxidase 2 inhibitor. Antioxid Redox Signal 23:358–374.
Houghton CA, Fassett RG, and Coombes JS (2013) Sulforaphane: translational research from laboratory bench to clinic. Nutr Rev 71:709–726.
Hung RJ, Boffetta P, Brennan P, Malaveille C, Gelatti U, Placidi D, Carta A, Hau-tefeuille A, and Porru S (2004) Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Car-cinogenesis 25:973–978.
Ill-Raga G, Palomer E, Ramos-Fernández E, Guix FX, Bosch-Morató M, Guivernau B, Tajes M, Valls-Comamala V, Jiménez-Conde J, Ois A, et al. (2015) Fibrinogen nitrotyrosination after ischemic stroke impairs thrombolysis and promotes neuronal death. Biochim Biophys Acta Mol Basis Dis 1852:421–428.
Inayama M, Hashimoto N, Tokoro T, and Shiozaki H (2007) Involvement of oxidative stress in experimentally induced reflux esophagitis and esophageal cancer. Hep-atogastroenterology 54:761–765.
Jagnandan D, Church JE, Banfi B, Stuehr DJ, Marrero MB, and Fulton DJR (2007) Novel mechanism of activation of NADPH oxidase 5. calcium sensitization via phosphorylation. J Biol Chem 282:6494–6507.
Jantschko W, Furtmüller PG, Zederbauer M, Neugschwandtner K, Lehner I, Jako-pitsch C, Arnhold J, and Obinger C (2005) Exploitation of the unusual thermody-namic properties of human myeloperoxidase in inhibitor design. Biochem Pharmacol 69:1149–1157.
Jaquet V, Scapozza L, Clark RA, Krause K-H, and Lambeth JD (2009) Small-molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic tar-gets. Antioxid Redox Signal 11:2535–2552.
Jaruvongvanich V, Ahuja W, Wirunsawanya K, Wijarnpreecha K, and Ungprasert P (2017) Hyperuricemia is associated with nonalcoholic fatty liver disease activity score in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 29:1031–1035.
Jha JC, Banal C, Okabe J, Gray SP, Hettige T, Chow BSM, Thallas-Bonke V, De Vos L, Holterman CE, Coughlan MT, et al. (2017) NADPH oxidase Nox5 accelerates renal injury in diabetic nephropathy. Diabetes 66:2691–2703.
Joo JH, Huh J-E, Lee JH, Park DR, Lee Y, Lee SG, Choi S, Lee HJ, Song S-W, Jeong Y, et al. (2016) A novel pyrazole derivative protects from ovariectomy-induced osteoporosis through the inhibition of NADPH oxidase. Sci Rep 6:22389.
Jordan A and Gresser U (2018) Side effects and interactions of the xanthine oxidase inhibitor febuxostat. Pharmaceuticals (Basel) 11:51.
Kaludercic N, Carpi A, Nagayama T, Sivakumaran V, Zhu G, Lai EW, Bedja D, De Mario A, Chen K, Gabrielson KL, et al. (2014) Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts. Antioxid Redox Signal 20:267–280.
Kaludercic N, Takimoto E, Nagayama T, Feng N, Lai EW, Bedja D, Chen K, Gabrielson KL, Blakely RD, Shih JC, et al. (2010) Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Circ Res 106:193–202.
Kaur H and Halliwell B (1994) Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheuma-toid patients. FEBS Lett 350:9–12.
Khan AA, Quinn TJ, Hewitt J, Fan Y, and Dawson J (2016) Serum uric acid level and association with cognitive impairment and dementia: systematic review and meta-analysis. Age (Dordr) 38:16.
Khan SQ, Kelly D, Quinn P, Davies JE, and Ng LL (2007) Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart 93:826–831.
Kim H, Wei Y, Lee JY, Wu Y, Zheng Y, Moskowitz MA, and Chen JW (2016) Mye-loperoxidase inhibition increases neurogenesis after ischemic stroke. J Pharmacol Exp Ther 359:262–272.
Kim Y, Yoon S, Kim SJ, Kim JS, Cheong J-W, and Min YH (2012) Myeloperoxidase expression in acute myeloid leukemia helps identifying patients to benefit from transplant. Yonsei Med J 53:530–536.
Kiss PJ, Knisz J, Zhang Y, Baltrusaitis J, Sigmund CD, Thalmann R, Smith RJH, Verpy E, and Bánfi B (2006) Inactivation of NADPH oxidase organizer 1 results in severe imbalance. Curr Biol 16:208–213.
Kleinschnitz C, Grund H, Wingler K, Armitage ME, Jones E, Mittal M, Barit D, Schwarz T, Geis C, Kraft P, et al. (2010) Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol 8: e1000479.
Kleinschnitz C, Mencl S, Kleikers PWM, Schuhmann MK, López MG, Casas AI, Sürün B, Reif A, and Schmidt HHHW (2016) NOS knockout or inhibition but not disrupting PSD-95-NOS interaction protect against ischemic brain damage. J Cereb Blood Flow Metab 36:1508–1512.
Kotsonis P, Frey A, Fröhlich LG, Hofmann H, Reif A, Wink DA, Feelisch M, and Schmidt HH (1999) Autoinhibition of neuronal nitric oxide synthase: distinct effects of reactive nitrogen and oxygen species on enzyme activity. Biochem J 340: 745–752.
Kotsonis P, Fröhlich LG, Raman CS, Li H, Berg M, Gerwig R, Groehn V, Kang Y, Al-Masoudi N, Taghavi-Moghadam S, et al. (2001) Structural basis for pterin antag-onism in nitric-oxide synthase. Development of novel 4-oxo-pteridine antagonists of (6R)-5,6,7,8-tetrahydrobiopterin. J Biol Chem 276:49133–49141.
Kotsonis P, Fröhlich LG, Shutenko ZV, Horejsi R, Pfleiderer W, and Schmidt HH (2000) Allosteric regulation of neuronal nitric oxide synthase by tetrahy-drobiopterin and suppression of auto-damaging superoxide. Biochem J 346: 767–776.
Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, and Witztum JL; Nutrition Committee of the American Heart Association Council on Nutrition, Physical Activity, and Metabolism (2004) Antioxidant vitamin supplements and cardiovascular disease. Circulation 110:637–641.
Krzyszton-Russjan J, Zielonka D, Jackiewicz J, Kusmirek S, Bubko I, Klimberg A, Marcinkowski JT, and Anuszewska EL (2013) A study of molecular changes relating to energy metabolism and cellular stress in people with Huntington’s disease: looking for biomarkers. J Bioenerg Biomembr 45:71–85.
Kumar MJ, Nicholls DG, and Andersen JK (2003) Oxidative α-ketoglutarate de-hydrogenase inhibition via subtle elevations in monoamine oxidase B levels results in loss of spare respiratory capacity: implications for Parkinson’s disease. J Biol Chem 278:46432–46439.
Lan T, Kisseleva T, and Brenner DA (2015) Deficiency of NOX1 or NOX4 prevents liver inflammation and fibrosis in mice through inhibition of hepatic stellate cell activation. PLoS One 10:e0129743.
Landmesser U, Spiekermann S, Preuss C, Sorrentino S, Fischer D, Manes C, Mueller M, and Drexler H (2007) Angiotensin II induces endothelial xanthine oxidase ac-tivation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol 27:943–948.
Langhauser F, Casas AI, Dao V-T-V, Guney E, Menche J, Geuss E, Kleikers PWM, López MG, Barabási A-L, Kleinschnitz C, et al. (2018) A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle re-laxation to direct neuroprotection. NPJ Syst Biol Appl 4:8.
Lapchak PA (2010) A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmac-other 11:1753–1763.
Lazarevic-Pasti T, Leskovac A, and Vasic V (2015) Myeloperoxidase inhibitors as potential drugs. Curr Drug Metab 16:168–190.
Lee M-S, Flammer AJ, Lerman LO, and Lerman A (2012) Personalized medicine in cardiovascular diseases. Korean Circ J 42:583–591.
Lee SR, An EJ, Kim J, and Bae YS (2020) Function of NADPH oxidases in diabetic nephropathy and development of nox inhibitors. Biomol Ther (Seoul) 28:25–33.
Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener H-C, Grotta J, Lyden P, Shuaib A, Hårdemark H-G, et al.; Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators (2006) NXY-059 for acute ischemic stroke. N Engl J Med 354: 588–600.
Lei S, Zhang P, Li W, Gao M, He X, Zheng J, Li X, Wang X, Wang N, Zhang J, et al. (2014) Pre-and posttreatment with edaravone protects CA1 hippocampus and enhances neurogenesis in the subgranular zone of dentate gyrus after transient global cerebral ischemia in rats. ASN Neuro 6:175909141455841.
Li J, Fu Y, Zhao B, Xiao Y, and Chen R (2014) Myeloperoxidase G463A polymorphism and risk of lung cancer. Tumour Biol 35:821–829.
Li Q, Youn J-Y, and Cai H (2015) Mechanisms and consequences of endothelial nitric oxide synthase dysfunction in hypertension. J Hypertens 33:1128–1136.
Li Y, Cifuentes-Pagano E, DeVallance ER, de Jesus DS, Sahoo S, Meijles DN, Koes D, Camacho CJ, Ross M, St Croix C, et al. (2019) NADPH oxidase 2 inhibitors CPP11G and CPP11H attenuate endothelial cell inflammation & vessel dysfunction and restore mouse hind-limb flow. Redox Biol 22:101143.
Li Y and Pagano PJ (2017) Microvascular NADPH oxidase in health and disease. Free Radic Biol Med 109:33–47.
Libby P, Ridker PM, and Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473:317–325.
Liu AC, Lee M, McManus BM, and Choy JC (2012) Induction of endothelial nitric oxide synthase expression by IL-17 in human vascular endothelial cells: implications for vascular remodeling in transplant vasculopathy. J Immunol 188: 1544–1550.
Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, et al.; HOPE and HOPE-TOO Trial Investigators (2005) Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293:1338–1347.
Ludolph AC, Schuster J, Dorst J, Dupuis L, Dreyhaupt J, Weishaupt JH, Kassubek J, Weiland U, Petri S, Meyer T, et al.; RAS-ALS Study Group (2018) Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol 17:681–688.
Luecke K, Gasiorowski L, Herold S, Brychta N, Gallerani G, Krahn T, Fabbri F, Dyszkiewicz W, and Schumann C (2015) The GILUPI CellCollector as an in vivo tool for circulating tumor cell enumeration and molecular characterization in lung cancer patients. J Clin Oncol 33:e22035.
Lum CT and Stahl SM (2012) Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression. CNS Spectr 17:107–120.
Maghzal GJ, Krause K-H, Stocker R, and Jaquet V (2012) Detection of reactive oxygen species derived from the family of NOX NADPH oxidases. Free Radic Biol Med 53:1903–1918.
Malle E, Furtmüller PG, Sattler W, and Obinger C (2007) Myeloperoxidase: a target for new drug development? Br J Pharmacol 152:838–854.
Manach C, Williamson G, Morand C, Scalbert A, and Rémésy C (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81 (1 Suppl):230S–242S.
Manni ME, Rigacci S, Borchi E, Bargelli V, Miceli C, Giordano C, Raimondi L, and Nediani C (2016) Monoamine oxidase is overactivated in left and right ven-tricles from ischemic hearts: an intriguing therapeutic target. Oxid Med Cell Longev 2016:4375418.
Marchioli R (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 354:447–455.
Martinon F, Pétrilli V, Mayor A, Tardivel A, and Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241.
McCord JM and Fridovich I (1988) Superoxide dismutase: the first twenty years (1968-1988). Free Radic Biol Med 5:363–369.
McDougall GJ, Fyffe S, Dobson P, and Stewart D (2005) Anthocyanins from red wine--their stability under simulated gastrointestinal digestion. Phytochemistry 66:2540–2548.
McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, et al.; Huntington Study Group 2CARE Investigators and Coordinators (2017) A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology 88:152–159.
Melichar VO, Behr-Roussel D, Zabel U, Uttenthal LO, Rodrigo J, Rupin A, Verbeuren TJ, Kumar H S A, and Schmidt HHHW (2004) Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclero-sis. Proc Natl Acad Sci USA 101:16671–16676.
Menche J, Sharma A, Kitsak M, Ghiassian SD, Vidal M, Loscalzo J, and Barabasi A-L (2015) Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science 347:1257601.
MeurerS,PiochS,PabstT,OpitzN,SchmidtPM,BeckhausT,WagnerK,Matt S, Gegenbauer K, Geschka S, et al. (2009) Nitric oxide-independent vasodila-tor rescues heme-oxidized soluble guanylate cyclase from proteasomal degra-dation. Circ Res 105:33–41.
Misko TP, Radabaugh MR, Highkin M, Abrams M, Friese O, Gallavan R, Bramson C, Hellio Le Graverand MP, Lohmander LS, and Roman D (2013) Characterization of nitrotyrosine as a biomarker for arthritis and joint injury. Osteoarthritis Cartilage 21:151–156.
Miyaji Y, Yoshimura S, Sakai N, Yamagami H, Egashira Y, Shirakawa M, Uchida K, Kageyama H, and Tomogane Y (2015) Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion: subanalysis of RESCUE-Japan Registry. Neurol Med Chir (Tokyo) 55:241–247.
Moens AL, Ketner EA, Takimoto E, Schmidt TS, O’Neill CA, Wolin MS, Alp NJ, Channon KM, and Kass DA (2011) Bi-modal dose-dependent cardiac response to tetrahydrobiopterin in pressure-overload induced hypertrophy and heart failure. J Mol Cell Cardiol 51:564–569.
Moreno JC, Bikker H, Kempers MJE, van Trotsenburg ASP, Baas F, de Vijlder JJM, Vulsma T, and Ris-Stalpers C (2002) Inactivating mutations in the gene for thyroid oxidase 2 (THOX2) and congenital hypothyroidism. N Engl J Med 347:95–102.
Morrow JD, Qiu W, Chhabra D, Rennard SI, Belloni P, Belousov A, Pillai SG, and Hersh CP (2015) Identifying a gene expression signature of frequent COPD exacerbations in peripheral blood using network methods. BMC Med Genomics 8:1 DOI: 10.1186/s12920-014-0072-y.
Mullan K, Cardwell CR, McGuinness B, Woodside JV, and McKay GJ (2018) Plasma antioxidant status in patients with Alzheimer’s disease and cognitively intact el-derly: a meta-analysis of case-control studies. J Alzheimers Dis 62:305–317.
Myung S-K, Ju W, Cho B, Oh S-W, Park SM, Koo B-K, and Park B-J; Korean Meta-Analysis Study Group (2013) Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ 346:f10.
Nagase M, Yamamoto Y, Miyazaki Y, and Yoshino H (2016) Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep 21:104–112.
Nagra RM, Becher B, Tourtellotte WW, Antel JP, Gold D, Paladino T, Smith RA, Nelson JR, and Reynolds WF (1997) Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol 78:97–107.
Narasimhulu CA and Vardhan S (2015) Therapeutic potential of Ocimum tenui-florum as MPO inhibitor with implications for atherosclerosis prevention. JMed Food 18:507–515.
Nastase M-V, Zeng-Brouwers J, Frey H, Hsieh LT-H, Poluzzi C, Beckmann J, Schroeder N, Pfeilschifter J, Lopez-Mosqueda J, Mersmann J, et al. (2016) An essential role for SHARPIN in the regulation of caspase 1 activity in sepsis. Am J Pathol 186:1206–1220.
Nedvetsky PI, Sessa WC, and Schmidt HHHW (2002) There’s NO binding like NOS binding: protein-protein interactions in NO/cGMP signaling. Proc Natl Acad Sci USA 99:16510–16512.
Nezis IP and Stenmark H (2012) p62 at the interface of autophagy, oxidative stress signaling, and cancer. Antioxid Redox Signal 17:786–793.
Nicholls SJ and Hazen SL (2005) Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 25:1102–1111.
Nlandu Khodo S, Dizin E, Sossauer G, Szanto I, Martin P-Y, Feraille E, Krause KH, and de Seigneux S (2012) NADPH-oxidase 4 protects against kidney fibrosis during chronic renal injury. J Am Soc Nephrol 23:1967–1976.
Nosengo N (2016) Can you teach old drugs new tricks? Nature 534:314–316.
Nossaman B, Pankey E, and Kadowitz P (2012) Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications. Crit Care Res Pract 2012:290805.
Odalys OC, William QP, Luis PY, Miladys OC, Reinaldo MG, and María PM (2015) Chronic granulomatous disease: a case report. Front Immunol 6.
Odell EW and Segal AW (1988) The bactericidal effects of the respiratory burst and the myeloperoxidase system isolated in neutrophil cytoplasts. Biochim Biophys Acta 971:266–274.
Ogier-Denis E, Mkaddem SB, and Vandewalle A (2008) NOX enzymes and Toll-like receptor signaling. Semin Immunopathol 30:291–300.
Ooi J, Hayden MR, and Pouladi MA (2015) Inhibition of excessive monoamine oxidase A/B activity protects against stress-induced neuronal death in Huntington disease. Mol Neurobiol 52:1850–1861.
Otomo E, Tohgi H, Kogure K, Hirai S, Takakura K, Terashi A, Gotoh F, Maruyama S, Tazaki Y, Shinohara Y, et al.; Edaravone Acute Infarction Study Group (2003) Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain in-farction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 15:222–229.
Paffenholz R, Bergstrom RA, Pasutto F, Wabnitz P, Munroe RJ, Jagla W, Heinzmann U, Marquardt A, Bareiss A, Laufs J, et al. (2004) Vestibular defects in head-tilt mice result from mutations in Nox3, encoding an NADPH oxidase. Genes Dev 18:486–491.
Pajares M, Cuadrado A, Engedal N, Jirsova Z, and Cahova M (2018) The role of free radicals in autophagy regulation: implications for ageing. Oxid Med Cell Longev 2018:2450748.
Pajares M, Cuadrado A, and Rojo AI (2017) Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases. Redox Biol 11: 543–553.
Pchejetski D, Kunduzova O, Dayon A, Calise D, Seguelas M-H, Leducq N, Seif I, Parini A, and Cuvillier O (2007) Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ Res 100:41–49.
Peng J-J, Xiong S-Q, Ding L-X, Peng J, and Xia X-B (2019) Diabetic retinopathy: focus on NADPH oxidase and its potential as therapeutic target. Eur J Pharmacol 853:381–387.
Pérez-Torres I, Guarner-Lans V, and Rubio-Ruiz ME (2017) Reductive stress in inflammation-associated diseases and the pro-oxidant effect of antioxidant agents. Int J Mol Sci 18:2098.
Pfeiffer S, Leopold E, Schmidt K, Brunner F, and Mayer B (1996) Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement for bioactivation to the free acid, NG-nitro-L-arginine. Br J Pharmacol 118: 1433–1440.
Pirro M, Schillaci G, Mannarino MR, Savarese G, Vaudo G, Siepi D, Paltriccia R, and Mannarino E (2007) Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia. Nutr Metab Cardiovasc Dis 17:436–441.
Ramsaransing G, Teelken A, Prokopenko VM, Arutjunyan AV, and De Keyser J (2003) Low leucocyte myeloperoxidase activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 74:953–955.
Ray RS and Katyal A (2016) Myeloperoxidase: bridging the gap in neuro-degeneration. Neurosci Biobehav Rev 68:611–620.
Reif A, Fröhlich LG, Kotsonis P, Frey A, Bömmel HM, Wink DA, Pfleiderer W, and Schmidt HHHW (1999) Tetrahydrobiopterin inhibits monomerization and is consumed during catalysis in neuronal NO synthase. J Biol Chem 274: 24921–24929.
Rezende F, Löwe O, Helfinger V, Prior K-K, Walter M, Zukunft S, Fleming I, Weissmann N, Brandes RP, and Schröder K (2016) Unchanged NADPH oxidase activity in Nox1-Nox2-Nox4 triple knockout mice: what do NADPH-stimulated chemiluminescence assays really detect? Antioxid Redox Signal 24:392–399.
Richardot P, Charni-Ben Tabassi N, Toh L, Marotte H, Bay-Jensen A-C, Miossec P, and Garnero P (2009) Nitrated type III collagen as a biological marker of nitric oxide-mediated synovial tissue metabolism in osteoarthritis. Osteoarthritis Cartilage 17:1362–1367.
Rigutto S, Hoste C, Grasberger H, Milenkovic M, Communi D, Dumont JE, Corvilain B, Miot F, and De Deken X (2009) Activation of dual oxidases Duox1 and Duox2: differential regulation mediated by camp-dependent protein kinase and protein kinase C-dependent phosphorylation. J Biol Chem 284:6725–6734.
Rocha-Penha L, Caldeira-Dias M, Tanus-Santos JE, de Carvalho Cavalli R, and Sandrim VC (2017) Myeloperoxidase in hypertensive disorders of pregnancy and its relation with nitric oxide. Hypertension 69:1173–1180.
Rojo AI, Pajares M, García-Yagüe AJ, Buendia I, Van Leuven F, Yamamoto M, López MG, and Cuadrado A (2018) Deficiency in the transcription factor NRF2 worsens inflammatory parameters in a mouse model with combined tauopathy and amy-loidopathy. Redox Biol 18:173–180.
Rojo AI, Pajares M, Rada P, Nuñez A, Nevado-Holgado AJ, Killik R, Van Leuven F, Ribe E, Lovestone S, Yamamoto M, et al. (2017) NRF2 deficiency replicates tran-scriptomic changes in Alzheimer’s patients and worsens APP and TAU pathology. Redox Biol 13:444–451.
Rojo AI, Rada P, Mendiola M, Ortega-Molina A, Wojdyla K, Rogowska-Wrzesinska A, Hardisson D, Serrano M, and Cuadrado A (2014) The PTEN/NRF2 axis promotes human carcinogenesis. Antioxid Redox Signal 21:2498–2514.
Rousset F, Carnesecchi S, Senn P, and Krause K-H (2015) Nox3-targeted therapies for inner ear pathologies. Curr Pharm Des 21:5977–5987.
Saed GM, Ali-Fehmi R, Jiang ZL, Fletcher NM, Diamond MP, Abu-Soud HM, and Munkarah AR (2010) Myeloperoxidase serves as a redox switch that regulates apoptosis in epithelial ovarian cancer. Gynecol Oncol 116:276–281.
Sakuma M, Toyoda S, Arikawa T, Koyabu Y, Kato T, Adachi T, Suwa H, Narita JI, Anraku K, Ishimura K, et al.; For Excited UA study Investigators (2018) The effects of xanthine oxidase inhibitor in patients with chronic heart failure com-plicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol. Clin Exp Nephrol 22:1379–1386.
Salehi B, Martorell M, Arbiser JL, Sureda A, Martins N, Maurya PK, Sharifi-Rad M, Kumar P, and Sharifi-Rad J (2018) Antioxidants: positive or negative actors? Biomolecules 8:124.
Sandner P and Stasch JP (2017) Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Respir Med 122 (Suppl 1):S1–S9.
Sandner P, Zimmer DP, Milne GT, Follmann M, Hobbs A, and Stasch J-P (2019) Soluble guanylate cyclase stimulators and activators. Handb Exp Pharmacol DOI: 10.1007/164_2018_197 [published ahead of print].
Sarangarajan R, Meera S, Rukkumani R, Sankar P, and Anuradha G (2017) Anti-oxidants: friend or foe? Asian Pac J Trop Med 10:1111–1116.
Sareila O, Kelkka T, Pizzolla A, Hultqvist M, and Holmdahl R (2011) NOX2 complex-derived ROS as immune regulators. Antioxid Redox Signal 15:2197–2208.
Sargeant LA, Khaw KT, Bingham S, Day NE, Luben RN, Oakes S, Welch A, and Wareham NJ (2001) Fruit and vegetable intake and population glycosylated haemoglobin levels: the EPIC-Norfolk Study. Eur J Clin Nutr 55:342–348.
Scannell JW, Blanckley A, Boldon H, and Warrington B (2012) Diagnosing the de-cline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 11:191–200.
Scherz-Shouval R and Elazar Z (2011) Regulation of autophagy by ROS: physiology and pathology. Trends Biochem Sci 36:30–38.
Schewe T and Sies H (2005) Myeloperoxidase-induced lipid peroxidation of LDL in the presence of nitrite. Protection by cocoa flavanols. Biofactors 24:49–58.
Schildknecht S, Weber A, Gerding HR, Pape R, Robotta M, Drescher M, Marquardt A, Daiber A, Ferger B, and Leist M (2014) The NOX1/4 inhibitor GKT136901 as selective and direct scavenger of peroxynitrite. Curr Med Chem 21:365–376.
Schimrigk S, Brune N, Hellwig K, Lukas C, Bellenberg B, Rieks M, Hoffmann V, Pöhlau D, and Przuntek H (2006) Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 13:604–610.
Schmidt HHHW, Baumbach J, Loscalzo J, Agusti A, Silverman EK, and Azevedo V (2018) Expert panel discusses the importance of systems medicine. Syst Med (New Rochelle) 1:3–8.
Schmidt HHHW, Nau H, Wittfoht W, Gerlach J, Prescher K-E, Klein MM, Nir-oomand F, and Böhme E (1988) Arginine is a physiological precursor of endothelium-derived nitric oxide. Eur J Pharmacol 154:213–216.
Schmidt HHHW, Pollock JS, Nakane M, Gorsky LD, Förstermann U, and Murad F (1991) Purification of a soluble isoform of guanylyl cyclase-activating-factor syn-thase. Proc Natl Acad Sci USA 88:365–369.
Schmidt HHHW, Smith RM, Nakane M, and Murad F (1992) Ca2+/calmodulin-dependent NO synthase type I: a biopteroflavoprotein with Ca2+/calmodulin-independent diaphorase and reductase activities. Biochemistry 31:3243–3249.
Schmidt HHHW, Stocker R, Vollbracht C, Paulsen G, Riley D, Daiber A, and Cuadrado A (2015) Antioxidants in translational medicine. Antioxid Redox Signal 23:1130–1143.
Schmidt HHHW and Walter U (1994) NO at work. Cell 78:919–925.
Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, et al. (2017) O×-2 and H2O2-mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate. Cancer Cell 31: 487–500.e8.
Schork NJ (2015) Personalized medicine: time for one-person trials. Nature 520: 609–611.
Schramm A, Matusik P, Osmenda G, and Guzik TJ (2012) Targeting NADPH oxi-dases in vascular pharmacology. Vascul Pharmacol 56:216–231.
Schramm L, La M, Heidbreder E, Hecker M, Beckman JS, Lopau K, Zimmermann J, Rendl J, Reiners C, Winderl S, et al. (2002) L-arginine deficiency and supple-mentation in experimental acute renal failure and in human kidney trans-plantation. Kidney Int 61:1423–1432.
Schröder K, Wandzioch K, Helmcke I, and Brandes RP (2009) Nox4 acts as a switch between differentiation and proliferation in preadipocytes. Arterioscler Thromb Vasc Biol 29:239–245.
Schürmann C, Rezende F, Kruse C, Yasar Y, Löwe O, Fork C, van de Sluis B, Bremer R, Weissmann N, Shah AM, et al. (2015) The NADPH oxidase Nox4 has anti-atherosclerotic functions. Eur Heart J 36:3447–3456.
Schwerd T, Bryant RV, Pandey S, Capitani M, Meran L, Cazier J-B, Jung J, Mondal K, Parkes M, Mathew CG, et al.; WGS500 Consortium Oxford IBD cohort study investigators COLORS in IBD group investigators UK IBD Genetics Consortium INTERVAL Study (2018) NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease. Mucosal Immunol 11:562–574.
Sena LA and Chandel NS (2012) Physiological roles of mitochondrial reactive oxygen species. Mol Cell 48:158–167.
Seredenina T, Nayernia Z, Sorce S, Maghzal GJ, Filippova A, Ling S-C, Basset O, Plastre O, Daali Y, Rushing EJ, et al. (2016) Evaluation of NADPH oxidases as drug targets in a mouse model of familial amyotrophic lateral sclerosis. Free Radic Biol Med 97:95–108.
Sharma A, Menche J, Huang CC, Ort T, Zhou X, Kitsak M, Sahni N, Thibault D, Voung L, Guo F, et al. (2015) A disease module in the interactome explains disease heterogeneity, drug response and captures novel pathways and genes in asthma. Hum Mol Genet 24:3005–3020.
Shekelle PG, Morton SC, Jungvig LK, Udani J, Spar M, Tu W, J Suttorp M, Coulter I, Newberry SJ, and Hardy M (2004) Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease. J Gen Intern Med 19:380–389.
Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, Gokce N, Keaney JF Jr., Penn MS, Sprecher DL, et al. (2003) Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 289: 1675–1680.
Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener H-C, Ashwood T, Wasiewski WW, and Emeribe U; SAINT II Trial Investigators (2007) NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 357:562–571.
Sies H (2019) Oxidative stress, Stress: Physiology, Biochemistry, and Pathology pp 153–163, Elsevier.
Smith JD (2010) Myeloperoxidase, inflammation, and dysfunctional high-density li-poprotein. J Clin Lipidol 4:382–388.
Sorato E, Menazza S, Zulian A, Sabatelli P, Gualandi F, Merlini L, Bonaldo P, Canton M, Bernardi P, and Di Lisa F (2014) Monoamine oxidase inhibition prevents mitochondrial dysfunction and apoptosis in myoblasts from patients with collagen VI myopathies. Free Radic Biol Med 75:40–47.
Soubhye J, Aldib I, Delporte C, Prévost M, Dufrasne F, and Antwerpen PV (2016) Myeloperoxidase as a target for the treatment of inflammatory syndromes: mechanisms and structure activity relationships of inhibitors. Curr Med Chem 23: 3975–4008.
Soubhye J, Aldib I, Prévost M, Elfving B, Gelbcke M, Podrecca M, Conotte R, Colet J-M, Furtmüller PG, Delporte C, et al. (2014) Hybrid molecules inhibiting myeloperox-idase activity and serotonin reuptake: a possible new approach of major depressive disorders with inflammatory syndrome. J Pharm Pharmacol 66:1122–1132.
Soubhye J, Chikh Alard I, Aldib I, Prévost M, Gelbcke M, De Carvalho A, Furtmüller PG, Obinger C, Flemmig J, Tadrent S, et al. (2017) Discovery of novel potent reversible and irreversible myeloperoxidase inhibitors using virtual screening procedure. J Med Chem 60:6563–6586.
Spiekermann S, Landmesser U, Dikalov S, Bredt M, Gamez G, Tatge H, Reepschl-äger N, Hornig B, Drexler H, and Harrison DG (2003) Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 107:1383–1389.
Stamp LK, Khalilova I, Tarr JM, Senthilmohan R, Turner R, Haigh RC, Winyard PG, and Kettle AJ (2012) Myeloperoxidase and oxidative stress in rheumatoid arthritis. Rheumatology (Oxford) 51:1796–1803.
Stasch J-P, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H S AK, Meurer S, Deile M, Taye A, Knorr A, Lapp H, et al. (2006) Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116: 2552–2561.
Statland JM, Moore D, Wang Y, Walsh M, Mozaffar T, Elman L, Nations SP, Mit-sumoto H, Fernandes JA, Saperstein D, et al.; Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium (2019) Rasagiline for amyo-trophic lateral sclerosis: a randomized, controlled trial. Muscle Nerve 59:201–207.
Steinhubl SR (2008) Why have antioxidants failed in clinical trials? Am J Cardiol 101:14D–19D.
Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, and Mitchinson MJ (1996) Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347:781–786.
Stover JF, Belli A, Boret H, Bulters D, Sahuquillo J, Schmutzhard E, Zavala E, Ungerstedt U, Schinzel R, and Tegtmeier F; NOSTRA Investigators (2014) Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in mod-erate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). J Neurotrauma 31:1599–1606.
Sturza A, Leisegang MS, Babelova A, Schröder K, Benkhoff S, Loot AE, Fleming I, Schulz R, Muntean DM, and Brandes RP (2013) Monoamine oxidases are media-tors of endothelial dysfunction in the mouse aorta. Hypertension 62:140–146.
Subbarayan PR, Lima M, and Ardalan B (2007) Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experi-ence. Acta Oncol 46:557–561.
Sun Y-Y, Li Y, Wali B, Li Y, Lee J, Heinmiller A, Abe K, Stein DG, Mao H, Sayeed I, et al. (2015) Prophylactic edaravone prevents transient hypoxic-ischemic brain injury: implications for perioperative neuroprotection. Stroke 46:1947–1955.
Tamariz L, Hernandez F, Bush A, Palacio A, and Hare JM (2014) Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm 11:1102–1108.
Teixeira G, Szyndralewiez C, Molango S, Carnesecchi S, Heitz F, Wiesel P, and Wood JM (2017) Therapeutic potential of NADPH oxidase 1/4 inhibitors. Br J Pharmacol 174:1647–1669.
Tian R, Ding Y, Peng Y-Y, and Lu N (2017) Inhibition of myeloperoxidase-and neutrophil-mediated hypochlorous acid formation in vitro and endothelial cell injury by (-)-epigallocatechin gallate. J Agric Food Chem 65:3198–3203.
Tonks NK (2005) Redox redux: revisiting PTPs and the control of cell signaling. Cell 121:667–670.
Touyz RM, Anagnostopoulou A, Camargo LL, Rios FJ, and Montezano AC (2019a) Vascular biology of superoxide-generating NADPH oxidase 5-implications in hypertension and cardiovascular disease. Antioxid Redox Signal 30:1027–1040.
Touyz RM, Anagnostopoulou A, Rios F, Montezano AC, and Camargo LL (2019b) NOX5: molecular biology and pathophysiology. Exp Physiol 104:605–616.
Tschopp J (2011) Mitochondria: sovereign of inflammation? Eur J Immunol 41: 1196–1202.
Tsikas D and Duncan MW (2014) Mass spectrometry and 3-nitrotyrosine: strategies, controversies, and our current perspective. Mass Spectrom Rev 33:237–276.
Üllen A, Singewald E, Konya V, Fauler G, Reicher H, Nusshold C, Hammer A, Kratky D, Heinemann A, Holzer P, et al. (2013) Myeloperoxidase-derived oxidants induce blood-brain barrier dysfunction in vitro and in vivo. PLoS One 8:e64034.
van der Vliet A, Danyal K, and Heppner DE (2018) Dual oxidase: a novel therapeutic target in allergic disease. Br J Pharmacol 175:1401–1418.
van der Vliet A, Eiserich JP, Halliwell B, and Cross CE (1997) Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential ad-ditional mechanism of nitric oxide-dependent toxicity. J Biol Chem 272:7617–7625.
van der Weyden L, Arends MJ, Campbell AD, Bald T, Wardle-Jones H, Griggs N, Velasco-Herrera MDC, Tüting T, Sansom OJ, Karp NA, et al.; Sanger Mouse Genetics Project (2017) Genome-wide in vivo screen identifies novel host regulators of metastatic colonization. Nature 541:233–236.
Vargas-Santos AB, Peloquin CE, Zhang Y, and Neogi T (2018) Association of chronic kidney disease with allopurinol use in gout treatment. JAMA Intern Med 178: 1526–1533.
Viollet B, Horman S, Leclerc J, Lantier L, Foretz M, Billaud M, Giri S, and Andreelli F (2010) AMPK inhibition in health and disease. Crit Rev Biochem Mol Biol 45: 276–295.
Vita JA, Brennan M-L, Gokce N, Mann SA, Goormastic M, Shishehbor MH, Penn MS, Keaney JF Jr., and Hazen SL (2004) Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 110:1134–1139.
Vivekananthan DP, Penn MS, Sapp SK, Hsu A, and Topol EJ (2003) Use of antiox-idant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 361:2017–2023.
Wang J, Yu Y, Li X, Li D, Xu C, Yuan J, Wei S, Li X, Yang K, Zheng D, et al. (2018a) Serum uric acid levels and decreased estimated glomerular filtration rate in patients with type 2 diabetes: a cohort study and meta-analysis. Diabetes Metab Res Rev 34:e3046.
Wang X, Elksnis A, Wikström P, Walum E, Welsh N, and Carlsson P-O (2018b) The novel NADPH oxidase 4 selective inhibitor GLX7013114 counteracts human islet cell death in vitro. PLoS One 13:e0204271.
Wannamethee SG, Lowe GDO, Rumley A, Bruckdorfer KR, and Whincup PH (2006) Associations of vitamin C status, fruit and vegetable intakes, and markers of inflammation and hemostasis. Am J Clin Nutr 83:567–574, NaN–727.
Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, Ntalla I, Surendran P, Liu C, Cook JP, et al.; International Consortium of Blood Pressure (ICBP) 1000G Analyses BIOS Consortium Lifelines Cohort Study Understanding Society Scientific group CHD Exome+ Consortium ExomeBP Consortium T2D-GENES Consortium GoT2DGenes Consortium Cohorts for Heart and Ageing Research in Genome Epi-demiology (CHARGE) BP Exome Consortium International Genomics of Blood Pressure (iGEN-BP) Consortium UK Biobank CardioMetabolic Consortium BP working group (2017) Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nat Genet 49:403–415.
Weber G, Rabbiosi S, Zamproni I, and Fugazzola L (2013) Genetic defects of hydrogen peroxide generation in the thyroid gland. J Endocrinol Invest 36:261–266.
Wei Z, Li X, Li X, Liu Q, and Cheng Y (2018) Oxidative stress in Parkinson’s disease: a systematic review and meta-analysis. Front Mol Neurosci 11:236.
Weimann A, Belling D, and Poulsen HE (2001) Measurement of 8-oxo-2'-deoxyguanosine and 8-oxo-2'-deoxyadenosine in DNA and human urine by high performance liquid chromatography-electrospray tandem mass spectrometry. Free Radic Biol Med 30: 757–764.
Wen M, Zhou B, Chen Y-H, Ma Z-L, Gou Y, Zhang C-L, Yu WF, and Jiao L (2017) Serum uric acid levels in patients with Parkinson’s disease: a meta-analysis. PLoS One 12:e0173731.
Wilkinson-BerkaJL,DeliyantiD,RanaI,MillerAG,AgrotisA,ArmaniR,Szyndralewiez C, Wingler K, Touyz RM, Cooper ME, et al. (2014) NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy. Antioxid Redox Signal 20:2726–2740.
Wingler K, Hermans JJ, Schiffers P, Moens A, Paul M, and Schmidt HH (2011) NOX1, 2, 4, 5: counting out oxidative stress. Br J Pharmacol 164:866–883.
Wu JB, Shao C, Li X, Li Q, Hu P, Shi C, Li Y, Chen Y-T, Yin F, Liao C-P, et al. (2014a) Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis. J Clin Invest 124:2891–2908.
Wu S, Sena E, Egan K, Macleod M, and Mead G (2014b) Edaravone improves functional and structural outcomes in animal models of focal cerebral ischemia: a systematic review. Int J Stroke 9:101–106.
Wu SM and Pizzo SV (2001) α(2)-Macroglobulin from rheumatoid arthritis synovial fluid: functional analysis defines a role for oxidation in inflammation. Arch Biochem Biophys 391:119–126.
Wu W, Chen Y, and Hazen SL (1999) Eosinophil peroxidase nitrates protein tyrosyl residues. Implications for oxidative damage by nitrating intermediates in eosino-philic inflammatory disorders. J Biol Chem 274:25933–25944.
Ximenes VF, Maghzal GJ, Turner R, Kato Y, Winterbourn CC, and Kettle AJ (2009) Serotonin as a physiological substrate for myeloperoxidase and its superoxide-dependent oxidation to cytotoxic tryptamine-4,5-dione. Biochem J 425:285–293.
Xu Q, Choksi S, Qu J, Jang J, Choe M, Banfi B, Engelhardt JF, and Liu ZG (2016) NADPH oxidases are essential for macrophage differentiation. J Biol Chem 291: 20030–20041.
Xu X, Zhang H, Wang K, Tu T, and Jiang Y (2017) Protective effect of edaravone against carbon monoxide induced apoptosis in rat primary cultured astrocytes. Biochem Res Int 2017:5839762.
Yang J, Li J, Wang Q, Xing Y, Tan Z, and Kang Q (2018) Novel NADPH oxidase inhibitor VAS2870 suppresses TGF-β-dependent epithelial-to-mesenchymal transition in retinal pigment epithelial cells. Int J Mol Med 42:123–130.
Yang M, Koo SI, Song WO, and Chun OK (2011) Food matrix affecting anthocyanin bioavailability: review. Curr Med Chem 18:291–300.
Yoshikawa Y, Ago T, Kuroda J, Wakisaka Y, Tachibana M, Komori M, Shibahara T, Nakashima H, Nakashima K, and Kitazono T (2019) Nox4 promotes neural stem/precursor cell proliferation and neurogenesis in the hippocampus and restores memory function following trimethyltin-induced injury. Neuroscience 398:193–205.
Youdim MBH, Edmondson D, and Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295–309.
Yu G, Liang Y, Huang Z, Jones DW, Pritchard KA Jr., and Zhang H (2016) Inhibition of myeloperoxidase oxidant production by N-acetyl lysyltyrosylcysteine amide reduces brain damage in a murine model of stroke. JNeuroinflammation 13:119.
Yun J, Mullarky E, Lu C, Bosch KN, Kavalier A, Rivera K, Roper J, Chio IIC, Giannopoulou EG, Rago C, et al. (2015) Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350:1391–1396.
Zhang M, Brewer AC, Schröder K, Santos CXC, Grieve DJ, Wang M, Anilkumar N, Yu B, Dong X, Walker SJ, et al. (2010) NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci USA 107:18121–18126.
Zhang P and Itan Y (2019) Biological network approaches and applications in rare disease studies. Genes (Basel) 10:797.
Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, and Hazen SL (2001) Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286:2136–2142.
Zielonka J, Cheng G, Zielonka M, Ganesh T, Sun A, Joseph J, Michalski R, O’Brien WJ, Lambeth JD, and Kalyanaraman B (2014) High-throughput assays for su-peroxide and hydrogen peroxide: design of a screening workflow to identify inhibitors of NADPH oxidases. J Biol Chem 289:16176–16189.
Zuo L, Zhou T, Pannell BK, Ziegler AC, and Best TM (2015) Biological and physiological role of reactive oxygen species--the good, the bad and the ugly. Acta Physiol (Oxf) 214:329–348.
